| Symbol | NEXI |
|---|---|
| Name | NEXIMMUNE, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 20877 United States MD 9119 Gaither Road |
| Telephone | (301) 825-9810 |
| Fax | — |
| — | |
| Website | https://neximmune.com/ |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001538210 |
| Description | NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The companys product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. Additional info from OTC: |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form 25-NSE - NexImmune, Inc. Filed: 2024-09-06 AccNo: 0001354457-24-000653 Size: 4 KB
Read morePink Current symbol attribute type Security_Name was changed. Previous value: -. New value: NEXIMMUNE INC.
Read moreNew Form S-8 POS - NexImmune, Inc. Filed: 2024-08-27 AccNo: 0001193125-24-207772 Size: 22 KB
Read moreNew Form S-8 POS - NexImmune, Inc. Filed: 2024-08-27 AccNo: 0001193125-24-207769 Size: 22 KB
Read moreNew Form S-8 POS - NexImmune, Inc. Filed: 2024-08-27 AccNo: 0001193125-24-207763 Size: 22 KB
Read moreNew Form POS AM - NexImmune, Inc. Filed: 2024-08-27 AccNo: 0001193125-24-207752 Size: 20 KB
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: NEXIMMUNE INC.
Read moreGenprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
Read more